The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Pharma industry trends 2025. Find 3 standout insights from Evaluate’s World Preview 2025 webinar, including the rise of integrated biotechs & China’s growing role. Watch now on demand.| Evaluate
Biotech industry insights. Discover the key factors for biotech commercialization success, including strategic planning, hiring, and funding.| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
All parts of the pharma ecosystem are touched by speculation about AI. From drug discovery to clinical trials.| Evaluate
Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Forecasting serves to help pharmaceutical companies identify market opportunities and risks, particularly when taking a sales-based approach.| Evaluate
Good pharmaceutical forecasting requires robust processes to comply with best practices and create accurate results. Find out what the processes are.| Evaluate
Over the last 10 years, large pharma companies have spent an average of $120bn across pharma R&D and business development investments.| Evaluate
Our World Preview report features pharma forecasts out to 2030. The theme this year is “Pharma’s Growth Boost”.| Evaluate
Missed our webinar on orphan drugs? Catch up on the discussion with experts Melanie Senior, Puru Gaur, and Stephanie Léouzon on demand.| Evaluate
Empower your pharmaceutical forecasting with FC365. Streamline processes, save time, and enhance efficiency with our pharma-specific SaaS platform.| Evaluate
Neurology is experiencing a revival with notable clinical advancements and increased deal activity from pharmaceutical giants.| Evaluate